Therapeutic targets and signaling pathways of active components of QiLing decoction against castration-resistant prostate cancer based on network pharmacology

被引：2
作者：
Cao, Hongwen [1 ]
Wang, Dan [1 ]
Gao, Renjie [1 ]
Li, Chenggong [2 ]
Feng, Yigeng [1 ]
Chen, Lei [1 ]
机构：
[1] Shanghai Univ Tradit Chinese Med, LONGHUA Hosp, Urol, Shanghai, Peoples R China
[2] Linshu Hosp Tradit Chinese Med, Androl Urol, Linyi, Shandong, Peoples R China
来源：
PEERJ | 2022年 / 10卷
基金：
中国国家自然科学基金;
关键词：
QiLing decoction; Castration-resistant prostate cancer; Network pharmacology; Active components; Signaling pathways; Tumor growth; GROWTH;
D O I：
10.7717/peerj.13481
中图分类号：
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
QiLing decoction (QLD) is a traditional Chinese medicine compound. This study aims to explore the therapeutic effect of QLD in castration-resistant prostate cancer (CRPC) and its potential bio-targets. A total of 51 active components and QLD 149 targets were identified using bioinformatics analysis. Additionally, five optimal hub target genes were screened including tumor protein P53 (TP53), interleukin-6 (IL-6), vascular endothelial growth factor-A (VEGF-A), caspase-3 (CASP-3), and estrogen receptor-1 (ESR-1). The interrelated network between active components of QLD and their potential targets was constructed. The molecular function, biological processes, and signaling pathways of QLD-against CRPC were identified. Moreover, QLD was found to efficiently exert a repressive effect on CRPC tumor growth mainly by suppressing the activation of HIF-alpha/VEGFA and TNF-alpha/IL6 signaling pathways, and increasing the P53 expression level. These results successfully indicated the potential anti-CRPC mechanism of the active components of QLD.
引用
收藏
页数：20
相关论文
共 38 条
[1]   Linc00963 Promote Cell Proliferation and Tumor Growth in Castration-Resistant Prostate Cancer by Modulating miR-655/TRIM24 Axis [J].
Bai, Minghua ;
He, Chenchen ;
Shi, Shengjia ;
Wang, Mincong ;
Ma, Jinlu ;
Yang, Pengtao ;
Dong, Yiping ;
Mou, Xingyi ;
Han, Suxia .
FRONTIERS IN ONCOLOGY, 2021, 11
[2]   Dysregulation of the vascular endothelial growth factor and semaphorin ligand-receptor families in prostate cancer metastasis [J].
Bender, R. Joseph ;
Mac Gabhann, Feilim .
BMC SYSTEMS BIOLOGY, 2015, 9
[3]   Influences of TP53 and the anti-aging DDR1 receptor in controlling Raf/MEK/ERK and PI3K/Akt expression and chemotherapeutic drug sensitivity in prostate cancer cell lines [J].
Chappell, William H. ;
Candido, Saverio ;
Abrams, Stephen L. ;
Akula, Shaw M. ;
Steelman, Linda S. ;
Martelli, Alberto M. ;
Ratti, Stefano ;
Cocco, Lucio ;
Cervello, Melchiorre ;
Montalto, Giuseppe ;
Nicoletti, Ferdinando ;
Libra, Massimo ;
McCubrey, James A. .
AGING-US, 2020, 12 (11) :10194-10210
[4]  
CHEN C, PHY TOMEDICINE INT J, V85, DOI DOI 10.1016/J.PHYMED.2021.153514
[5]   Olaparib for Metastatic Castration-Resistant Prostate Cancer [J].
de Bono, J. ;
Mateo, J. ;
Fizazi, K. ;
Saad, F. ;
Shore, N. ;
Sandhu, S. ;
Chi, K. N. ;
Sartor, O. ;
Agarwal, N. ;
Olmos, D. ;
Thiery-Vuillemin, A. ;
Twardowski, P. ;
Mehra, N. ;
Goessl, C. ;
Kang, J. ;
Burgents, J. ;
Wu, W. ;
Kohlmann, A. ;
Adelman, C. A. ;
Hussain, M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (22) :2091-2102
[6]   Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer [J].
Fizazi, Karim ;
Shore, Neal ;
Tammela, Teuvo L. ;
Ulys, Albertas ;
Vjaters, Egils ;
Polyakov, Sergey ;
Jievaltas, Mindaugas ;
Luz, Murilo ;
Alekseev, Boris ;
Kuss, Iris ;
Kappeler, Christian ;
Snapir, Amir ;
Sarapohja, Toni ;
Smith, Matthew R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (13) :1235-1246
[7]   Enhancement of anticancer activity of docetaxel by combination with Fuzheng Yiliu decoction in a mouse model of castration-resistant prostate cancer [J].
Fu, Wei ;
Hone, Zhiming ;
You, Xujun ;
Din, Jing ;
Chen, Baishu ;
Zhao, Beibei ;
Yuan, Gengyan ;
Li, Qixin .
BIOMEDICINE & PHARMACOTHERAPY, 2019, 118
[8]   Astragalus Polysaccharides Inhibits Tumorigenesis and Lipid Metabolism Through miR-138-5p/SIRT1/SREBP1 Pathway in Prostate Cancer [J].
Guo, Shanqi ;
Ma, Baojie ;
Jiang, Xingkang ;
Li, Xiaojiang ;
Jia, Yingjie .
FRONTIERS IN PHARMACOLOGY, 2020, 11
[9]   Characterising the castration-resistant prostate cancer population: a systematic review [J].
Kirby, M. ;
Hirst, C. ;
Crawford, E. D. .
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2011, 65 (11) :1180-1192
[10]   Anti-colorectal cancer biotargets and biological mechanisms of puerarin: Study of molecular networks [J].
Li, Jun ;
Guo, Chao ;
Lu, Xiuli ;
Tan, Wenwen .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2019, 858
1234